Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: BIS Research Inc. | PRODUCT CODE: 1065019

Cover Image

PUBLISHER: BIS Research Inc. | PRODUCT CODE: 1065019

Oncology Precision Medicine Market - A Global and Regional Analysis: Focus on Ecosystem and Application - Analysis and Forecast, 2020-2031

PUBLISHED:
PAGES: 273 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF and Excel (1-3 User License)
USD 5250
PDF and Excel (Global License)
USD 8100

Add to Cart

“Global Oncology Precision Medicine Market to Reach $1,28,891.6 Million by 2031.”

Market Report Coverage - Oncology Precision Medicine

Market Segmentation

  • Ecosystem - Precision Therapeutics, Applied Sciences, Digital Health and Information Technology, Precision Diagnostics
  • Application - Solid Tumor and Hematological Malignancies

Regional Segmentation

  • North America: U.S., Canada
  • Europe: Germany, France, Italy, U.K., Spain, and Rest-of- Europe
  • Asia-Pacific: Japan, China, India, Australia, South Korea, and Rest-of-Asia-Pacific
  • Latin America: Brazil, Mexico, and Rest-of-Latin America
  • Rest-of-the-World

Market Growth Drivers

  • Increasing Incidence of Cancer Globally
  • Decreasing Trial and Error-Based Drug Prescription Through Pharmacogenomics
  • Increasing Usage of Predictive Biomarker for Cancer Diagnostics
  • Rapid Technological Advancements related to Oncology Precision Medicine
  • Decreasing Cost and Increase in the Output of Genomic Sequencing

Market Challenges

  • Large Scale Data Integration, Analysis, and Establishment of Secure Data Libraries
  • Inadequate Reimbursement Scenario for Precision Medicine
  • Lack of Expertise, Education, and Awareness for Precision Medicine Implementation

Market Opportunities

  • Unprecedented Improvements in Disease Modelling via In-Silico, In-Vitro, and In-Vivo Methods
  • Expansion into the Emerging Markets
  • Rising Number of Initiatives for Precision Oncology Research

Key Companies Profiled

Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Pacific Biosciences of California, Inc., PerkinElmer Inc., QIAGEN, Thermo Fisher Scientific Inc., BGI Group, ASURAGEN, INC., Almac Group Ltd., MDxHealth, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Myriad Genetics, Inc., OPKO Health, Inc., Quest Diagnostics Incorporated, Novartis AG.

Key Questions Answered in this Report:

  • How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment?
  • What are the major market drivers, restraints, and opportunities in the global oncology precision medicine market?
  • What are the underlying structures resulting in the emerging trends within the global oncology precision medicine market?
  • How is each segment of the global oncology precision medicine market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
  • What are the key developmental strategies implemented by the major players to sustain in the competitive market?
  • What are the key regulatory implications in developed and developing regions for oncology precision medicine?
  • Who are the leading players with significant offerings to the global oncology precision medicine market? What is the current market dominance for each of these leading players?
  • What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which ecosystem in the oncology precision medicine type has the most promising growth?
  • What are the major applications employed in the global oncology precision medicine market? Which is the dominating application?
  • Who are the key manufacturers in the global oncology precision medicine market, and what are their contributions? Also, what is the growth potential of each major oncology precision medicine manufacturer?
  • What is the scope of the global oncology precision medicine market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which oncology precision medicine technology and end user dominate these regions?
  • What are the emerging trends in the global oncology precision medicine market? How are these trends revolutionizing the diagnostic procedure?
  • Which technologies are anticipated to break through the oncology precision medicine regime?
  • Which companies are anticipated to be highly disruptive in the future and why?
  • What are the regulatory procedures that are required to unify the approval process for the emerging oncology precision medicine market? How will these enhance the reimbursement scenario?
  • What are the gaps in regularizing oncology precision medicine adoption in regular healthcare routines? How are these gaps being tackled?

Market Overview

Precision medicine is a concept that collectively integrates the outcomes and the endeavors of research and healthcare. The ability to tailor the diagnostics and therapeutics offered to the patients is the key to precision medicine. The combination of biotechnology development, digitization of healthcare, the public investment led to the evolution of the personalization of disease-based therapies. The precision medicine concept is a systematic process aiming to achieve victory over a disease such as cancer. Cancer is the major focus of various precision medicine initiatives, and precision oncology centers around matching the most accurate and precise treatment to each cancer patient on the basis of an individual's matching genetic profile that could ultimately let them benefit from the treatment offered.

The global oncology precision medicine market was valued at $45,174.2 million in 2020 and is expected to reach $1,28,891.6 million by 2031, growing at a CAGR of 10.05% during the forecast period 2021-2031.

Factors fueling the growth of the market include increasing incidence of cancer globally, decreasing trial and error-based drug prescription through pharmacogenomics, increasing usage of predictive biomarkers for cancer diagnostics, and rapid technological advancements related to oncology precision medicine.

Within the research report, the market has been segmented based on ecosystem, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the prevalence of cancer globally has created a buzz among companies to invest in oncology precision medicine.

Based on region, North America holds the largest share, owing to rising cancer prevalence and improvised regulatory policies pertaining to precision oncology in the region. However, the Asia-Pacific and Europe regions are anticipated to grow at the fastest CAGR during the forecast period.

Product Code: BHP1015SB

Table of Contents

1 Markets

  • 1.1 Industry Outlook
    • 1.1.1 Introduction
  • 1.2 Evolution of Precision Medicine for Cancer Management and Treatment
  • 1.3 Applications of Precision Medicine in Oncology
    • 1.3.1 Identifying Genetic Mutations and Risks of Cancer Through Precision Diagnostics
    • 1.3.2 Promising Technological Developments Supporting Precision Oncology
      • 1.3.2.1 Low-Throughput Genomic Sequencing to High-Throughput Genomic Sequencing
      • 1.3.2.2 Multicell Hybrid Detection to Single-Cell Precision Detection
      • 1.3.2.3 Advancing Applications of ctDNA Detection Technology
      • 1.3.2.4 CRISPR/Cas Technology
  • 1.4 Impact of COVID-19 Pandemic on Global Oncology Precision Medicine Market
    • 1.4.1 Disruption of Oncology Precision Medicine Due to COVID-19
    • 1.4.2 COVID-19 Affecting Supply Chain of Oncology Precision Medicine-Based Therapies
    • 1.4.3 Interruption in Research and Clinical Development and Commercial Operation
      • 1.4.3.1 Research and Clinical Development
    • 1.4.4 Commercial Operation and Access
    • 1.4.5 Navigating Crisis Recovery and Looking to the Future
  • 1.5 Market Dynamics
    • 1.5.1 Impact Analysis
    • 1.5.2 Market Drivers
      • 1.5.2.1 Increasing Incidence of Cancer Globally
      • 1.5.2.2 Decreasing Trial and Error-Based Drug Prescription Through Pharmacogenomics
      • 1.5.2.3 Increasing Usage of Predictive Biomarker for Cancer Diagnostics
      • 1.5.2.4 Rapid Technological Advancements related to Oncology Precision Medicine
      • 1.5.2.5 Decreasing Cost and Increase in the Output of Genomic Sequencing
    • 1.5.3 Restraints
      • 1.5.3.1 Large Scale Data Integration, Analysis, and Establishment of Secure Data Libraries
      • 1.5.3.2 Inadequate Reimbursement Scenario for Precision Medicine
      • 1.5.3.3 Barriers in the Advancement of Precision Medicine
        • 1.5.3.3.1 Regulatory Barriers
      • 1.5.3.4 Lack of Expertise, Education, and Awareness for Precision Medicine Implementation
  • 1.6 Market Opportunities
    • 1.6.1 Unprecedented Improvements in Disease Modelling via In-Silico, In-Vitro, and In-Vivo Methods
    • 1.6.2 Expansion into the Emerging Markets
    • 1.6.3 Rising Number of Initiatives for Precision Oncology Research
  • 1.7 Competitive Landscape
    • 1.7.1 Acquisitions
    • 1.7.2 Synergistic Activities
    • 1.7.3 Product Launches, Approvals, and Upgradations
    • 1.7.4 Business Expansion
    • 1.7.5 Market Share Analysis
    • 1.7.6 Growth Share Analysis
      • 1.7.6.1 Growth Share Analysis (by Application)
      • 1.7.6.2 Growth Share Analysis (by Ecosystem)
  • 1.8 Industry Insights
    • 1.8.1 Legal and Regulatory Framework and Requirements
    • 1.8.2 North America
      • 1.8.2.1 Regulatory Requirements in U.S.
    • 1.8.3 Europe
      • 1.8.3.1 U.K.
        • 1.8.3.1.1 Regulatory Requirements in U.K.
          • 1.8.3.1.1.1 The Cancer Plan
    • 1.8.4 Asia-Pacific
  • 1.9 Legal Requirements and Framework by MHLW
  • 1.1 Legal Requirement and Framework by NMPA
  • 1.11 Patent Analysis
    • 1.11.1 Patent Filing Trend
      • 1.11.1.1 Patent Analysis (by Region)
      • 1.11.1.2 Patent Analysis (by Country)

2 Global Oncology Precision Medicine Market, by Ecosystem, $ Million, 2020-2031

  • 2.1 Overview
    • 2.1.1 Precision Therapeutics
      • 2.1.1.1 Clinical Trials
      • 2.1.1.2 Biomarker Testing
      • 2.1.1.3 Drug Discovery and Research
      • 2.1.1.4 Gene Therapy
      • 2.1.1.5 Cell Therapy
    • 2.1.2 Applied Sciences
      • 2.1.2.1 Genomics
        • 2.1.2.1.1 Polymerase Chain Reaction (PCR)
        • 2.1.2.1.2 Precision Medicine Next-Generation Sequencing
        • 2.1.2.1.3 Genome Editing
        • 2.1.2.1.4 Other Technologies
      • 2.1.2.2 Pharmacogenomics
      • 2.1.2.3 Other Applied Sciences
    • 2.1.3 Digital Health and Information Technology
      • 2.1.3.1 Clinical Decision Support System (CDSS)
      • 2.1.3.2 Big Data Analytics
      • 2.1.3.3 IT Infrastructure
      • 2.1.3.4 Genomics Informatics
      • 2.1.3.5 In-Silico Informatics
      • 2.1.3.6 Mobile Health
    • 2.1.4 Precision Diagnostics
      • 2.1.4.1 Molecular Diagnostics (MDx)
      • 2.1.4.2 Medical Imaging

3 Global Oncology Precision Medicine Market, by Application, $ Million, 2020-2031

  • 3.1 Overview
    • 3.1.1 Solid Tumor
      • 3.1.1.1 Breast Cancer
      • 3.1.1.2 Lung Cancer
      • 3.1.1.3 Colorectal Cancer
      • 3.1.1.4 Prostate Cancer
      • 3.1.1.5 Cervical Cancer
      • 3.1.1.6 Other Cancer
    • 3.1.2 Hematological Malignancies (HMs)
      • 3.1.2.1 Leukemia
      • 3.1.2.2 Lymphoma
      • 3.1.2.3 Myeloma or Multiple Myeloma (MM)
      • 3.1.2.4 Other Hematological Malignancies

4 Global Oncology Precision Medicine Market, by Regions, $ Million, 2020-2031

  • 4.1 Overview
  • 4.2 North America
    • 4.2.1 Key Competitors (by Ecosystem)
    • 4.2.2 North America Oncology Precision Medicine Market (by Application)
    • 4.2.3 Key Trends in the North America Oncology Precision Medicine Market
    • 4.2.4 U.S.
    • 4.2.5 Canada
  • 4.3 Europe
    • 4.3.1 Key Competitors (by Ecosystem)
    • 4.3.2 Europe Oncology Precision Medicine Market (by Application)
    • 4.3.3 Key Trends of Europe Oncology Precision Medicine Market
    • 4.3.4 Germany
    • 4.3.5 U.K.
    • 4.3.6 France
    • 4.3.7 Italy
    • 4.3.8 Spain
    • 4.3.9 Rest-of-Europe
  • 4.4 Asia-Pacific
    • 4.4.1 Key Competitors (by Ecosystem)
    • 4.4.2 Asia-Pacific Oncology Precision Medicine Market (by Application)
    • 4.4.3 Key Trends in the Asia-Pacific Oncology Precision Medicine Market
    • 4.4.4 China
    • 4.4.5 India
    • 4.4.6 Japan
    • 4.4.7 Australia
    • 4.4.8 South Korea
    • 4.4.9 Rest-of-Asia-Pacific
  • 4.5 Latin America (LATAM)
    • 4.5.1 Key Competitors (by Ecosystem)
    • 4.5.2 Latin America Oncology Precision Medicine Market (by Application)
    • 4.5.3 Key Trends in the Latin America Oncology Precision Medicine Market
    • 4.5.4 Brazil
    • 4.5.5 Mexico
    • 4.5.6 Rest-of-Latin America
  • 4.6 Rest-of-the-World (RoW)
    • 4.6.1 Key Competitors (by Ecosystem)
    • 4.6.2 Rest-of-the-World Oncology Precision Medicine Market (by Application)
    • 4.6.3 Key Trends in the Rest-of-the-World Oncology Precision Medicine Market

5 Markets - Competitive Benchmarking & Company Profiles

  • 5.1 Overview
  • 5.2 Agilent Technologies, Inc.
    • 5.2.1 Company Overview
    • 5.2.2 Role of Agilent Technologies, Inc. in the Global Oncology Precision Medicine Market
    • 5.2.3 Key Competitors of the Company
    • 5.2.4 Financials
    • 5.2.5 Key Insights About Financial of the Company
    • 5.2.6 Corporate Strategies
      • 5.2.6.1 Mergers and Acquisitions
      • 5.2.6.2 Synergistic Activities
      • 5.2.6.3 Business Expansion and Funding
      • 5.2.6.4 Product Launches and Upgradation
    • 5.2.7 SWOT Analysis
  • 5.3 Bio-Rad Laboratories, Inc.
    • 5.3.1 Company Overview
    • 5.3.2 Role of Bio-Rad Laboratories, Inc. in the Global Oncology Precision Medicine Market
    • 5.3.3 Key Competitors of the Company
    • 5.3.4 Financials
    • 5.3.5 Key Insights About Financial Health of the Company
    • 5.3.6 Corporate Strategies
      • 5.3.6.1 Product Launches and upgradation
    • 5.3.7 SWOT Analysis
  • 5.4 Illumina, Inc.
    • 5.4.1 Company Overview
    • 5.4.2 Role of Illumina, Inc. in the Global Oncology Precision Medicine Market
    • 5.4.3 Key Competitors of the Company
    • 5.4.4 Financials
    • 5.4.5 Key Insights About Financial Health of the Company
    • 5.4.6 Corporate Strategies
      • 5.4.6.1 Mergers and Acquisition
      • 5.4.6.2 Synergistic Activities
      • 5.4.6.3 Business Expansion and Funding
      • 5.4.6.4 Product Launches and Upgradation
    • 5.4.7 SWOT Analysis
  • 5.5 Pacific Biosciences of California, Inc.
    • 5.5.1 Company Overview
    • 5.5.2 Role of Pacific Biosciences of California, Inc. in the Global Oncology Precision Medicine Market
    • 5.5.3 Key Competitors of the Company
    • 5.5.4 Financials
    • 5.5.5 Key Insights About Financial Health of the Company
    • 5.5.6 Corporate Strategies
      • 5.5.6.1 Mergers and Acquisition
      • 5.5.6.2 Synergistic Activities
      • 5.5.6.3 Product Launches and Upgradation
    • 5.5.7 SWOT Analysis
  • 5.6 PerkinElmer Inc.
    • 5.6.1 Company Overview
    • 5.6.2 Role of PerkinElmer Inc. in the Global Oncology Precision Medicine Market
    • 5.6.3 Key Competitors of the Company
    • 5.6.4 Financials
    • 5.6.5 Key Insights About Financial Health of the Company
    • 5.6.6 Corporate Strategies
      • 5.6.6.1 Mergers and Acquisition:
      • 5.6.6.2 Synergistic Activities
      • 5.6.6.3 Business Expansion and Funding
      • 5.6.6.4 Product Launches and Upgradation
    • 5.6.7 SWOT Analysis
  • 5.7 QIAGEN
    • 5.7.1 Company Overview
    • 5.7.2 Role of QIAGEN in the Global Oncology Precision Medicine Market
    • 5.7.3 Key Competitors of the Company
    • 5.7.4 Financials
    • 5.7.5 Key Insights About Financial Health of the Company
    • 5.7.6 Corporate Strategies
      • 5.7.6.1 Mergers and Acquisition
      • 5.7.6.2 Synergistic Activities
      • 5.7.6.3 Business Expansion and Funding
      • 5.7.6.4 Product Launches and Upgradation
    • 5.7.7 SWOT Analysis
  • 5.8 Thermo Fisher Scientific Inc.
    • 5.8.1 Company Overview
    • 5.8.2 Role of Thermo Fisher Scientific Inc. in the Global Oncology Precision Medicine Market
    • 5.8.3 Key Competitors of the Company
    • 5.8.4 Financials
    • 5.8.5 Key Insights About Financial Health of the Company
    • 5.8.6 Corporate Strategies
      • 5.8.6.1 Mergers and Acquisition
      • 5.8.6.2 Synergistic Activities
      • 5.8.6.3 Business Expansion and Funding
      • 5.8.6.4 Product Launches and Upgradation
    • 5.8.7 SWOT Analysis
  • 5.9 BGI Group
    • 5.9.1 Company Overview
    • 5.9.2 Role of BGI Group in the Global Oncology Precision Medicine Market
    • 5.9.3 Key Competitors of the Company
    • 5.9.4 Corporate Strategies
      • 5.9.4.1 Mergers and Acquisitions
      • 5.9.4.2 Synergistic Activities
      • 5.9.4.3 Business Expansion and Funding
      • 5.9.4.4 Product Launches and Upgradation
    • 5.9.5 SWOT Analysis
  • 5.1 ASURAGEN, INC.
    • 5.10.1 Company Overview
    • 5.10.2 Role of ASURAGEN, INC. in Global Oncology Precision Medicine Market
    • 5.10.3 Key Competitors of the Company
    • 5.10.4 Corporate Strategies
      • 5.10.4.1 Synergistic Activities
      • 5.10.4.2 Business Expansion and Funding
      • 5.10.4.3 Product Launches and Upgradation
    • 5.10.5 SWOT Analysis
  • 5.11 Almac Group Ltd.
    • 5.11.1 Company Overview
    • 5.11.2 Role of Almac Group Ltd. in Global Oncology Precision Medicine Market
    • 5.11.3 Key Competitors of the Company
    • 5.11.4 Corporate Strategies
      • 5.11.4.1 Mergers and Acquisitions
      • 5.11.4.2 Synergistic Activities
      • 5.11.4.3 Business Expansion and Funding
      • 5.11.4.4 Product Launches and Upgradation
    • 5.11.5 SWOT Analysis
  • 5.12 MDxHealth
    • 5.12.1 Company Overview
    • 5.12.2 Role of MDxHealth in the Global Oncology Precision Medicine Market
    • 5.12.3 Key Competitors of the Company
    • 5.12.4 Financials
    • 5.12.5 Key Insights About Financial Health of the Company
    • 5.12.6 Corporate Strategies
      • 5.12.6.1 Mergers and Acquisitions
      • 5.12.6.2 Synergistic Activities
      • 5.12.6.3 Business Expansion and Funding
      • 5.12.6.4 Product Launches and Upgradation
    • 5.12.7 SWOT Analysis
  • 5.13 Abbott Laboratories
    • 5.13.1 Company Overview
    • 5.13.2 Role of Abbott Laboratories in the Global Oncology Precision Medicine Market
    • 5.13.3 Key Competitors of the Company
    • 5.13.4 Financials
    • 5.13.5 Corporate Strategies
      • 5.13.5.1 Mergers and Acquisitions
      • 5.13.5.2 Synergistic Activities
      • 5.13.5.3 Business Expansion and Funding
      • 5.13.5.4 Product launches and Upgradation
    • 5.13.6 SWOT Analysis
  • 5.14 F. Hoffmann-La Roche Ltd
    • 5.14.1 Company Overview
    • 5.14.2 Role of F. Hoffman-LA Roche Ltd in the Global Oncology Precision Medicine Market
    • 5.14.3 Key Competitors of the Company
    • 5.14.4 Financials
    • 5.14.5 Corporate Strategies
      • 5.14.5.1 Mergers and Acquisitions
      • 5.14.5.2 Synergistic Activities
      • 5.14.5.3 Business Expansion and Funding
      • 5.14.5.4 Product Launches and Upgradation
    • 5.14.6 SWOT Analysis
  • 5.15 Gilead Sciences, Inc.
    • 5.15.1 Company Overview
    • 5.15.2 Role of Gilead Sciences, Inc. in the Global Oncology Precision Medicine Market
    • 5.15.3 Key Competitors of the Company
    • 5.15.4 Financials
    • 5.15.5 Corporate Strategies
      • 5.15.5.1 Mergers and Acquisitions
      • 5.15.5.2 Synergistic Activities
      • 5.15.5.3 Business Expansion and Funding
      • 5.15.5.4 Product Launches and Upgradation
    • 5.15.6 SWOT Analysis
  • 5.16 Myriad Genetics, Inc
    • 5.16.1 Company Overview
    • 5.16.2 Role of Myriad Genetics, Inc. in the Global Oncology Precision Medicine Market
    • 5.16.3 Key Competitors of the Company
    • 5.16.4 Financials
    • 5.16.5 Key Insights About Financial Health of the Company
    • 5.16.6 Corporate Strategies
      • 5.16.6.1 Mergers and Acquisitions
      • 5.16.6.2 Synergistic Activities
      • 5.16.6.3 Business Expansion and Funding
      • 5.16.6.4 Product Launches and Upgradation
    • 5.16.7 SWOT Analysis
  • 5.17 OPKO Health, Inc.
    • 5.17.1 Company Overview
    • 5.17.2 Role of OPKO Health, Inc. in the Global Oncology Precision Medicine Market
    • 5.17.3 Key Competitors of the Company
    • 5.17.4 Financials
    • 5.17.5 Corporate Strategies
      • 5.17.5.1 Mergers and Acquisitions
      • 5.17.5.2 Synergistic Activities
      • 5.17.5.3 Business Expansion and Funding
      • 5.17.5.4 Product Launches and Upgradation
    • 5.17.6 SWOT Analysis
  • 5.18 Quest Diagnostics Incorporated
    • 5.18.1 Company Overview
    • 5.18.2 Role of Quest Diagnostics Incorporated in the Global Oncology Precision Medicine Market
    • 5.18.3 Key Competitors of the Company
    • 5.18.4 Financials
    • 5.18.5 Corporate Strategies
      • 5.18.5.1 Mergers and Acquisitions
      • 5.18.5.2 Synergistics Activities
      • 5.18.5.3 Business Expansion and Funding
      • 5.18.5.4 Product Launches and Upgradation
    • 5.18.6 SWOT Analysis
  • 5.19 Novartis AG
    • 5.19.1 Company Overview
    • 5.19.2 Role of Novartis AG in the Global Oncology Precision Medicine Market
    • 5.19.3 Key Competitors of the Company
    • 5.19.4 Financials
    • 5.19.5 Corporate Strategies
      • 5.19.5.1 Synergistic Activities
      • 5.19.5.2 Business Expansion and Funding
      • 5.19.5.3 Product Launches and Upgradation
    • 5.19.6 SWOT Analysis
  • 5.2 Emerging Companies
    • 5.20.1 Prelude Therapeutics
      • 5.20.1.1 Company Overview
    • 5.20.2 AceTech
      • 5.20.2.1 Company Overview
    • 5.20.3 Flatiron
      • 5.20.3.1 Company Overview
    • 5.20.4 Biosplice Therapeutics, Inc.
      • 5.20.4.1 Company Overview
Product Code: BHP1015SB

List of Figures

  • Figure 1: Overall Deaths Due to Key Cancer Causes, Million, 2012-2019
  • Figure 2: Global Oncology Precision Medicine Market, $Million, 2020-2031
  • Figure 3: Global Oncology Precision Medicine Market, Market Dynamics
  • Figure 4: Share of Key Developments and Strategies, January 2018-January 2022
  • Figure 5: Global Oncology Precision Medicine Market (by Ecosystem), $Million, 2020 Vs. 2031
  • Figure 6: Global Oncology Precision Medicine Market (by Application), $Million, 2020 Vs. 2031
  • Figure 7: Global Oncology Precision Medicine Market (by Region), 2020 Vs. 2031
  • Figure 8: Global Oncology Precision Medicine Market Research Methodology
  • Figure 9: Share of Total Number of Companies Profiled
  • Figure 10: Global Oncology Precision Medicine Market: Segmentation
  • Figure 11: Global Oncology Precision Medicine Market, $Million, 2020-2031
  • Figure 12: Evolution of Precision Medicine Technology
  • Figure 13: Molecular Diagnostics in Oncology
  • Figure 14: Number of Cancer Cases Diagnosed in the Netherlands (January 3, 2020 - April 5 2020)
  • Figure 15: Pre-COVID-19 and Post-COVID-19 Scenario of Global Oncology Precision Medicine Market, 2017-2025
  • Figure 16: Areas of Disruption in Clinical Development
  • Figure 17: Measure to Navigate Crisis Recovery
  • Figure 18: Global Oncology Precision Medicine Market - Market Dynamics
  • Figure 19: Estimated Tracheal, Bronchus and Lung Cancer Incidences (Region-Wise), 2020 and 2030(E)
  • Figure 20: Estimated Cancer Mortality (Region-Wise), 2020
  • Figure 21: Decreasing Cost and Increasing Output of Genome Sequencing, 2009-2025
  • Figure 22: Share of Key Developments and Strategies, January 2018-January 2022
  • Figure 23: Share of Acquisitions (by Company), January 2018-January 2022
  • Figure 24: Synergistic Activities Share (by Company), January 2018-January 2022
  • Figure 25: Product Launches and Approvals (by Company), January 2018-January 2022
  • Figure 26: Share of Business Expansion (by Company), January 2018-January 2022
  • Figure 27: Market Share Analysis for Global Oncology Precision Medicine Market, $Million, 2020
  • Figure 28: Growth Share Analysis of Global Oncology Precision Medicine Market (by Application), 2021-2031
  • Figure 29: Growth Share Analysis of Global Oncology Precision Medicine Market (by Ecosystem), 2021-2031
  • Figure 30: FDA Guidelines for CDx Approval
  • Figure 31: Year-Wise Analysis of Patents Related to Oncology Precision Medicine, January 2018-January 2022
  • Figure 32: Region-Wise Analysis of Patents Related to Oncology Precision Medicine, January 2018 - January 2022
  • Figure 33: Country-Wise Analysis of Patents Related to Oncology Precision Medicine, January 2018 - January 2022
  • Figure 34: Share of Global Oncology Precision Medicine Market (by Ecosystem), $Million, 2020 and 2031
  • Figure 35: Global Oncology Precision Medicine Market (Precision Therapeutics), $Million, 2020-2031
  • Figure 36: Global Oncology Precision Medicine Market (Clinical Trials), $Million, 2020-2031
  • Figure 37: Global Oncology Precision Medicine Market (Biomarker Testing), $Million, 2020-2031
  • Figure 38: Global Oncology Precision Medicine Market (Drug Discovery and Research), $Million, 2020-2031
  • Figure 39: Global Oncology Precision Medicine Market (Gene Therapy), $Million, 2020-2031
  • Figure 40: Global Oncology Precision Medicine Market (Cell Therapy), $Million, 2020-2031
  • Figure 41: Global Oncology Precision Medicine Market (Applied Sciences), $Million, 2020-2031
  • Figure 42: Global Oncology Precision Medicine Market (Genomics), $Million, 2020-2031
  • Figure 43: Global Oncology Precision Medicine Market (PCR), $Million, 2020-2031
  • Figure 44: Global Oncology Precision Medicine Market (Precision Medicine NGS), $Million, 2020-2031
  • Figure 45: Global Oncology Precision Medicine Market (Genome Editing), $Million, 2020-2031
  • Figure 46: Global Oncology Precision Medicine Market (Other Technologies) $Million, 2020-2031
  • Figure 47: Global Oncology Precision Medicine Market (Pharmacogenomics), $Million, 2020-2031
  • Figure 48: Global Oncology Precision Medicine Market (Other Applied Sciences), $Million, 2020-2031
  • Figure 49: Global Oncology Precision Medicine Market (Digital Health and Information Technology), $Million, 2020-2031
  • Figure 50: Global Oncology Precision Medicine Market (CDSS), $Million, 2020-2031
  • Figure 51: Global Oncology Precision Medicine Market (Big Data Analytics), $Million, 2020-2031
  • Figure 52: Global Oncology Precision Medicine Market (IT Infrastructure), $Million, 2020-2031
  • Figure 53: Global Oncology Precision Medicine Market (Genomics Informatics), $Million, 2020-2031
  • Figure 54: Global Oncology Precision Medicine Market (In-Silico Informatics), $Million, 2020-2031
  • Figure 55: Global Oncology Precision Medicine Market (Mobile Health), $Million, 2020-2031
  • Figure 56: Global Oncology Precision Medicine Market (Precision Diagnostics), $Million, 2020-2031
  • Figure 57: Global Oncology Precision Medicine Market (Molecular Diagnostics), $Million, 2020-2031
  • Figure 58: Global Oncology Precision Medicine Market (Medical Imaging), $Million, 2020-2031
  • Figure 59: Global Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031
  • Figure 60: Global Oncology Precision Medicine Market (Solid Tumor), $Million, 2020-2031
  • Figure 61: Global Oncology Precision Medicine Market (Breast Cancer), $Million, 2020-2031
  • Figure 62: Global Oncology Precision Medicine Market (Lung Cancer), $Million, 2020-2031
  • Figure 63: Global Oncology Precision Medicine Market (Colorectal Cancer), $Million, 2020-2031
  • Figure 64: Global Oncology Precision Medicine Market (Prostate Cancer), $Million, 2020-2031
  • Figure 65: Global Oncology Precision Medicine Market (Cervical Cancer), $Million, 2020-2031
  • Figure 66: Global Oncology Precision Medicine Market (Other Cancer), $Million, 2020-2031
  • Figure 67: Global Oncology Precision Medicine Market (Hematological Malignancies), $Million, 2020-2031
  • Figure 68: Global Oncology Precision Medicine Market (Leukemia), $Million, 2020-2031
  • Figure 69: Global Oncology Precision Medicine Market (Lymphoma), $Million, 2020-2031
  • Figure 70: Global Oncology Precision Medicine Market (Myeloma), $Million, 2020-2031
  • Figure 71: Global Oncology Precision Medicine Market (Other Hematological Malignancies), $Million, 2020-2031
  • Figure 72: Global Oncology Precision Medicine Market (by Region), 2020-2031
  • Figure 73: Share of North America Oncology Precision Medicine Market (by Country), $Million, 2020 and 2031
  • Figure 74: North America: Market Dynamics
  • Figure 75: North America Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031
  • Figure 76: U.S. Oncology Precision Medicine Market, $Million, 2020-2031
  • Figure 77: Canada Oncology Precision Medicine Market, $Million, 2020-2031
  • Figure 78: Europe Oncology Precision Medicine Market (by Country), $Million, 2020 and 2031
  • Figure 79: Europe: Market Dynamics
  • Figure 80: Europe Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031
  • Figure 81: Germany Oncology Precision Medicine Market, $Million, 2020-2031
  • Figure 82: U.K. Oncology Precision Medicine Market, Million, 2020-2031
  • Figure 83: France Oncology Precision Medicine Market, $Million, 2020-2031
  • Figure 84: Italy Oncology Precision Medicine Market, $Million, 2020-2031
  • Figure 85: Spain Oncology Precision Medicine Market, $Million, 2020-2031
  • Figure 86: Rest-of-Europe Oncology Precision Medicine Market, $Million, 2020-2031
  • Figure 87: APAC: Market Dynamics
  • Figure 88: Asia-Pacific Oncology Precision Medicine Market (by Country), $Million, 2020 and 2031
  • Figure 89: Asia-Pacific Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031
  • Figure 90: China Oncology Precision Medicine Market, $Million, 2020-2031
  • Figure 91: India Oncology Precision Medicine Market, $Million, 2020-2031
  • Figure 92: Japan Oncology Precision Medicine Market, $Million, 2020-2031
  • Figure 93: Australia Oncology Precision Medicine Market, Million, 2020-2031
  • Figure 94: South Korea Oncology Precision Medicine Market, Million, 2020-2031
  • Figure 95: Rest-of-Asia-Pacific Oncology Precision Medicine Market, $Million, 2020-2031
  • Figure 96: LATAM: Market Dynamics
  • Figure 97: Latin America Oncology Precision Medicine Market (by Country), $Million, 2020-2031
  • Figure 98: Latin America Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031
  • Figure 99: Brazil Oncology Precision Medicine Market, $Million, 2020-2031
  • Figure 100: Mexico Oncology Precision Medicine Market, Million, 2020-2031
  • Figure 101: Rest-of-Latin America Oncology Precision Medicine Market, $Million, 2020-2031
  • Figure 102: Rest-of-the-World Oncology Precision Medicine Market, $Million, 2020-2031
  • Figure 103: Rest-of-the-World Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031
  • Figure 104: Share of Key Company Profiled (22)
  • Figure 105: Agilent Technologies, Inc.: Product Portfolio
  • Figure 106: Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 107: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 108: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 109: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 110: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 111: Bio-Rad Laboratories, Inc.: Product Portfolio
  • Figure 112: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2018-2020
  • Figure 113: Bio-Rad Laboratories, Inc.: Revenue (by Business Segment), $Million, 2018-2020
  • Figure 114: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 115: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 116: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 117: Illumina, Inc.: Product Portfolio
  • Figure 118: Illumina, Inc.: Overall Financials, $Million, 2018-2020
  • Figure 119: Illumina, Inc.: Revenue (by Segment), $Million, 2018-2020
  • Figure 120: Illumina, Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 121: Illumina, Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 122: Illumina, Inc.: SWOT Analysis
  • Figure 123: Pacific Biosciences of California, Inc.: Product Portfolio
  • Figure 124: Pacific Biosciences of California, Inc.: Overall Financials, $Million, 2018-2020
  • Figure 125: Pacific Biosciences of California, Inc.: Revenue (by Segment), $Million, 2018-2020
  • Figure 126: Pacific Biosciences of California, Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 127: Pacific Biosciences of California, Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 128: Pacific Biosciences of California, Inc.: SWOT Analysis
  • Figure 129: PerkinElmer Inc.: Product Portfolio
  • Figure 130: PerkinElmer Inc.: Overall Financials, $Million, 2018-2020
  • Figure 131: PerkinElmer Inc.: Revenue (by Segment), $Million, 2018-2020
  • Figure 132: PerkinElmer Inc: Revenue (by Region), $Million, 2018-2020
  • Figure 133: PerkinElmer Inc. R&D Expenditure, $Million, 2018-2020
  • Figure 134: PerkinElmer Inc.: SWOT Analysis
  • Figure 135: QIAGEN: Portfolio
  • Figure 136: QIAGEN: Overall Financials, $Million, 2018-2020
  • Figure 137: QIAGEN: Revenue (by Segment), $Million, 2018-2020
  • Figure 138: QIAGEN: Revenue (by Region), $Million, 2018-2020
  • Figure 139: QIAGEN: R&D Expenditure, $Million, 2018-2020
  • Figure 140: QIAGEN: SWOT Analysis
  • Figure 141: Thermo Fisher Scientific, Inc.: Product Portfolio
  • Figure 142: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2018-2020
  • Figure 143: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), $Million, 2018-2020
  • Figure 144: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 145: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 146: Thermo Fisher Scientific Inc.: SWOT Analysis
  • Figure 147: BGI Product Portfolio
  • Figure 148: BGI Group: SWOT Analysis
  • Figure 149: ASURAGEN, INC.: Overall Product Offerings
  • Figure 150: ASURAGEN,INC.: SWOT Analysis
  • Figure 151: Almac Group Ltd.: Overall Product Offerings
  • Figure 152: Almac Group Ltd.: SWOT Analysis
  • Figure 153: MDxHealth: Service Portfolio
  • Figure 154: MDxHealth: Overall Financials, $Million, 2018-2020
  • Figure 155: MDxHealth: Revenue (by Segment), $Million, 2018-2020
  • Figure 156: MDxHealth: Revenue (by Region), $Million, 2018-2020
  • Figure 157: MDxHealth: R&D Expenditure, $Million, 2018-2020
  • Figure 158: MdxHealth: SWOT Analysis
  • Figure 159: Abbott Laboratories: Overall Product Offerings
  • Figure 160: Abbott Laboratories: Overall Financials, $Million, 2018-2020
  • Figure 161: Abbott Laboratories: Net Revenue (by Business Segment), $Million, 2018-2020
  • Figure 162: Abbott Laboratories: Net Revenue (by Region), $Million, 2018-2020
  • Figure 163: Abbott Laboratories: R&D Expenditure, $Million, 2018-2020
  • Figure 164: Abbott Laboratories: SWOT Analysis
  • Figure 165: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 166: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
  • Figure 167: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021
  • Figure 168: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021
  • Figure 169: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
  • Figure 170: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 171: Gilead Sciences, Inc.: Overall Product Portfolio
  • Figure 172: Gilead Sciences, Inc.: Overall Financials, $Million, 2018-2020
  • Figure 173: Gilead Sciences, Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 174: Gilead Sciences, Inc.: SWOT Analysis
  • Figure 175: Myriad Genetics, Inc.: Product Portfolio
  • Figure 176: Myriad Genetics, Inc.: Overall Financials, $Million, 2018-2020
  • Figure 177: Myriad Genetics, Inc.: Revenue (by Business Segment), $Million, 2018-2020
  • Figure 178: Myriad Genetics, Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 179: Myriad Genetics, Inc.: SWOT Analysis
  • Figure 180: OPKO Health, Inc.: Overall Product Portfolio
  • Figure 181: OPKO Health, Inc.: Overall Financials, $Million, 2018-2020
  • Figure 182: OPKO Health, Inc: Net Revenue (by Business Segment), $Million, 2018-2020
  • Figure 183: OPKO Health, Inc.: Net Revenue (by Region), $Million, 2018-2020
  • Figure 184: OPKO Health, Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 185: OPKO Health, Inc.: SWOT Analysis
  • Figure 186: Quest Diagnostics Incorporated: Overall Product Offerings
  • Figure 187: Quest Diagnostics Incorporated: Overall Financials, $Million, 2018-2020
  • Figure 188: Quest Diagnostics Incorporated: Revenue (by Business Segment), $Million, 2018-2020
  • Figure 189: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 190: Novartis AG: Overall Product Portfolio
  • Figure 191: Novartis AG: Overall Financials, $Million, 2019-2021
  • Figure 192: Novartis AG: Revenue (by Business Segment), $Million, 2019-2021
  • Figure 193: Novartis AG: SWOT Analysis

List of Tables

  • Table 1: Estimated New Cancer Cases (by Type) in U.S., 2022
  • Table 2: Potential Usage of Biomarkers in Cancer Diagnostics
  • Table 3: List of Initiatives for Precision Oncology Research in 2018
  • Table 4: List of Few FDA-Approved Pharmacogenomics Biomarkers in Drug Labeling
  • Table 5: Estimated New Cancer Cases and Deaths in the U.S., 2020
  • Table 6: Key Competitors of North America Oncology Precision Medicine (by Ecosystem), 2020
  • Table 7: Key Competitors of Europe Oncology Precision Medicine (by Ecosystem), 2020
  • Table 8: Key Competitors of Asia-Pacific Oncology Precision Medicine (by Ecosystem), 2020
  • Table 9: Key Competitors of Latin America Oncology Precision Medicine (by Ecosystem), 2020
  • Table 10: Key Competitors of Rest-of-the-World Oncology Precision Medicine (by Ecosystem), 2020
  • Table 11: BIS Insight for Prelude Therapeutics
  • Table 12: BIS Insight for AceTech
  • Table 13: BIS Insight for Flatiron
  • Table 14: BIS Insight for Biosplice Therapeutics, Inc.
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!